Treatment Targets for Right Ventricular Dysfunction in Pulmonary Arterial Hypertension

Research output: Contribution to journalReview articlepeer-review

38 Scopus citations


Right ventricle (RV) dysfunction is the strongest predictor of mortality in pulmonary arterial hypertension (PAH), but, at present, there are no therapies directly targeting the failing RV. Although there are shared molecular mechanisms in both RV and left ventricle (LV) dysfunction, there are important differences between the 2 ventricles that may allow for the development of RV-enhancing or RV-directed therapies. In this review, we discuss the current understandings of the dysregulated pathways that promote RV dysfunction, highlight RV-enriched or RV-specific pathways that may be of particular therapeutic value, and summarize recent and ongoing clinical trials that are investigating RV function in PAH. It is hoped that development of RV-targeted therapies will improve quality of life and enhance survival for this deadly disease.

Original languageEnglish (US)
Pages (from-to)1244-1260
Number of pages17
JournalJACC: Basic to Translational Science
Issue number12
StatePublished - Dec 2020

Bibliographical note

Publisher Copyright:
© 2020 The Authors


  • clinical trials
  • pulmonary arterial hypertension
  • right ventricle


Dive into the research topics of 'Treatment Targets for Right Ventricular Dysfunction in Pulmonary Arterial Hypertension'. Together they form a unique fingerprint.

Cite this